Geranylgeranylation facilitates proteasomal degradation of Rho G-proteins in human trabecular meshwork cells

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 3, 2011, Pages 1676-1683

  von Zee, Cynthia L ^a   Stubbs Jr , Evan B ^a,b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; EPOXOMICIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; MEVINOLIN; PHALLOIDIN; PROTEASOME; RHO FACTOR;

ACTIN FILAMENT; ARTICLE; CONTROLLED STUDY; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; GERANYLGERANYLATION; HUMAN; HUMAN CELL; ISOPRENYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; STRESS FIBER; TRABECULAR MESHWORK; TRABECULAR MESHWORK CELL; WESTERN BLOTTING;

ACTINS; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LOVASTATIN; MALE; OLIGOPEPTIDES; POLYISOPRENYL PHOSPHATES; PRENYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RHO GTP-BINDING PROTEINS; SESQUITERPENES; TRABECULAR MESHWORK;

EID: 79955929398     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6171     Document Type: Article

References (55)

1. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res. 2009;88:713-717.
2. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs. 2007;21:167-177.
3. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
4. Liu X, Hu Y, Filla MS, et al. The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Mol Vis. 2005;11:1112-1121.
5. Nakamura Y, Hirano S, Suzuki K, Seki K, Sagara T, Nishida T. Signaling mechanism of TGF-beta1-induced collagen contraction mediated by bovine trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2002;43:3465-3472.
6. Rao PV, Deng P, Maddala R, Epstein DL, Li CY, Shimokawa H. Expression of dominant negative Rho-binding domain of Rhokinase in organ cultured human eye anterior segments increases aqueous humor outflow. Mol Vis. 2005;11:288-297.
7. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029-1037.
8. Thieme H, Nuskovski M, Nass JU, Pleyer U, Strauss O, Wiederholt M. Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci. 2000;41:4240-4246.
9. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17-24.
10. Wennerberg K, Der CJ. Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci. 2004;117:1301-1312.
11. Wheeler AP, Ridley AJ. Why three Rho proteins?-RhoA, RhoB, RhoC, and cell motility. Exp Cell Res. 2004;301:43-49.
12. Ramachandran C, Satpathy M, Mehta D, Srinivas SP. Forskolin induces myosin light chain dephosphorylation in bovine trabecular meshwork cells. Curr Eye Res. 2008;33:169-176.
13. Shen X, Koga T, Park BC, SundarRaj N, Yue BY. Rho GTPase and cAMP/protein kinase A signaling mediates myocilin-induced alterations in cultured human trabecular meshwork cells. J Biol Chem. 2008;283:603-612.
14. Vittitow JL, Garg R, Rowlette LL, Epstein DL, O'Brien ET, Borras T. Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis. 2002;8:32-44.
15. Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol. 2010;298:C749-C763.
16. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133-142.
17. Delarue FL, Adnane J, Joshi B, et al. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene. 2007;26:633-640.
18. Prendergast GC. Actin'up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001;1:162-168.
19. Adamson P, Paterson HF, Hall A. Intracellular localization of the P21rho proteins. J Cell Biol. 1992;119:617-627.
20. Roberts PJ, Mitin N, Keller PJ, et al. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem. 2008;283:25150-25163.
21. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-269.
22. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Posttranslational modifications of p21rho proteins. J Biol Chem. 1992;267:20033-20038.
23. Gao J, Liao J, Yang GY. CAAX-box protein, prenylation process and arcinogenesis. Am J Translat Res. 2009;1:312-325.
24. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
25. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res. 2000;87:526-528.
26. Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem. 1995;270:7864-7868.
27. Von Zee CL, Richards MP, Bu P, Perlman JI, Stubbs EB Jr. Increased RhoA and RhoB protein accumulation in cultured human trabecular meshwork cells by lovastatin. Invest Ophthalmol Vis Sci. 2009;50:2816-2823.
28. Lebowitz PF, Du W, Prendergast GC. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem. 1997;272:16093-16095.
29. Allal C, Favre G, Couderc B, et al. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem. 2000;275:31001-31008.
30. Menge T, Hartung HP, Stuve O. Statins: a cure-all for the brain? Nat Rev Neurosci. 2005;6:325-331.
31. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358-370.
32. Sarkey JP, Richards MP, Stubbs EB Jr. Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome. J Neurochem. 2007;100:1265-1277.
33. Nagaoka T, Takahashi A, Sato E, et al. Effect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol. 2006;124:665-670.
34. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137:615-624.
35. Song J, Deng PF, Stinnett SS, Epstein DL, Rao PV. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci. 2005;46:2424-2432.
36. McGwin G, Jr., McNeal S, Owsley C, Girkin C, Epstein D, Lee PP. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol. 2004;122:822-826.
37. Pang IH, Shade DL, Clark AF, Steely HT, DeSantis L. Preliminary characterization of a transformed cell strain derived from human trabecular meshwork. Curr Eye Res. 1994;13:51-63.
38. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203: 401-412.
39. Walters CE, Pryce G, Hankey DJ, et al. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol. 2002;168:4087-4094.
40. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285-288.
41. Amano M, Chihara K, Kimura K, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997; 275:1308-1311.
42. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999; 96:10403-10408.
43. Rolli-Derkinderen M, Sauzeau V, Boyer L, et al. Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res. 2005;96: 1152-1160.
44. Liton PB, Gonzalez P, Epstein DL. The role of proteolytic cellular systems in trabecular meshwork homeostasis. Exp Eye Res. 2009; 88:724-728.
45. Hanna J, Finley D. A proteasome for all occasions. FEBS Lett. 2007;581:2854-2861.
46. Boyer L, Turchi L, Desnues B, et al. CNF1-induced ubiquitylation and proteasome destruction of activated RhoA is impaired in Smurf1_/_ cells. Mol Biol Cell. 2006;17:2489-2497.
47. Chen Y, Yang Z, Meng M, et al. Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell. 2009; 35:841-855.
48. Breusing N, Grune T. Regulation of proteasome-mediated protein degradation during oxidative stress and aging. Biol Chem. 2008; 389:203-209.
49. Liton PB, Lin Y, Gonzalez P, Epstein DL. Potential role of lysosomal dysfunction in the pathogenesis of primary open angle glaucoma. Autophagy. 2009;5:122-124.
50. Stamatakis K, Cernuda-Morollon E, Hernandez-Perera O, Perez-Sala D. Isoprenylation of RhoB is necessary for its degradation: a novel determinant in the complex regulation of RhoB expression by the mevalonate pathway. J Biol Chem. 2002;277:49389-49396.
51. Pop M, Aktories K, Schmidt G. Isotype-specific degradation of Rac activated by the cytotoxic necrotizing factor 1. J Biol Chem. 2004;279:35840-35848.
52. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science. 1995;268: 726-731.
53. Craiu A, Gaczynska M, Akopian T, et al. Lactacystin and clastolactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. 1997; 272:13437-13445.
54. Perez-Sala D, Boya P, Ramos I, Herrera M, Stamatakis K. The C-terminal sequence of RhoB directs protein degradation through an endo-lysosomal pathway. PloS one. 2009;4:e8117.
55. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke. 2006;37:2640-2643.